This Article Full Text Full Text (PDF) All Versions of this Article: 40/5/e298    most recent STROKEAHA.108.544619v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mayer, S. A. Articles by Schwab, S. Search for Related Content PubMed PubMed Citation Articles by Mayer, S. A. Articles by Schwab, S. Related Collections Other Stroke Treatment - Medical

(Stroke. 2009;40:e298.)
© 2009 American Heart Association, Inc.

Advances in Stroke 2008

Advances in Critical Care and Emergency Medicine

From the Neurological Intensive Care Unit (S.A.M.), Departments of Neurology and Neurosurgery, Columbia University Medical Center, New York, NY; and the Department of Neurology (S.S.), University of Erlangen, Erlangen, Germany.

Correspondence to Stephan A. Mayer, MD, FCCM, Neurological Institute, 710 W 168th Street, Box 39, New York, NY 10032. E-mail sam14@columbia.edu

Key Words: advances • critical care • emergency medicine

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
In 2008, there were clinical trial advances in 3 areas that will impact on the way stroke care is practiced in the emergency department and intensive care unit (ICU). These include (1) the positive results of the European Cooperative Acute Stroke Study (ECASS) III trial, extending the time window for intravenous thrombolytic therapy for acute ischemic stroke; (2) the negative results of 2 trials investigating the use of intensive insulin therapy in the ICU; and (3) new data from the Phase 2 Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT), investigating the role of intensive blood pressure (BP) control after intracerebral hemorrhage (ICH).

	ECASS III: Breaking the Time Barrier

 
Intravenous thrombolysis with alteplase is still the only approved treatment for acute ischemic stroke. However, the time window for applying this therapy, which significantly reduces morbidity but not mortality, up to now has been restricted to 3 hours after symptom onset.¹ Various stroke trials trying to expand this strict time window, selecting patients based on CT or MRI perfusion, and using thrombolytic agents other than recombinant tissue plasminogen activator (rtPA), have up until now failed to prove efficacy regarding clinical end points.^2–5 After a couple of years without any positive stroke trials, ECASS III adds on to the encouraging results of the pooled analyses of the ECASS and National Institute of Neurological Diseases and Stroke trials,⁶ now expanding the time window for CT-based treatment of acute ischemic stroke up to 4.5 hours.⁷

The ECASS III trial randomly assigned 821 patients either to receive 0.9 mg . . . [Full Text of this Article]